IOLCPNSEQ3FY238 February 2023

IOL Chemicals and Pharmaceuticals Limited

3,385words
1turns
0analyst exchanges
0executives
Key numbers — 40 extracted
rs 05
aceutical Business Segment-Specialty Chemicals Manufacturing Facilities Core sustainability pillars 05 Industry Overview Overview on Pharmaceutical Sector Overview on Chemical Sector 06 Way Forward
35%
017 Largest producer of Ibuprofen and the only company worldwide being backward integrated with ~35% Global share Spread over a sprawling campus of over 150 acres Key Highlights Largest producer
30%
a Zero Discharge Effluent Treatment Plant 2nd Largest producer of Iso Butyl Benzene (IBB) with ~30% Global share Customer base across 80 countries Over 20 products are commercialized with 8 produc
1,800 MT
ally. Apart from cost rationalisation, we have completed our capacity enhancement of Paracetamol by 1,800 MTPA to take total capacity to 3,600 MTPA with Backward integration of Para Amino Phenol (PAP) and we
3,600 MT
, we have completed our capacity enhancement of Paracetamol by 1,800 MTPA to take total capacity to 3,600 MTPA with Backward integration of Para Amino Phenol (PAP) and we expect this capacity enhancement to b
9.37%
to 3,600 MTPA with Backward integration of Para Amino Phenol (PAP) 530.12 Revenues 49.68 EBITDA 9.37% EBITDA Margin 24.15 Profit After Tax 4.56% PAT Margin 9MFY23 Financial Performance 1,646.75 R
4.56%
a Amino Phenol (PAP) 530.12 Revenues 49.68 EBITDA 9.37% EBITDA Margin 24.15 Profit After Tax 4.56% PAT Margin 9MFY23 Financial Performance 1,646.75 Revenues 147.59 EBITDA 8.96% EBITDA Margin
8.96%
fit After Tax 4.56% PAT Margin 9MFY23 Financial Performance 1,646.75 Revenues 147.59 EBITDA 8.96% EBITDA Margin 74.71 Profit After Tax 4.54% PAT Margin 6 Segmental highlights Chemical Segmen
4.54%
ncial Performance 1,646.75 Revenues 147.59 EBITDA 8.96% EBITDA Margin 74.71 Profit After Tax 4.54% PAT Margin 6 Segmental highlights Chemical Segment Operating Revenue net intersegment (Rs. cro
36%
ental break-up Geographical Break-up (Rs. crore) Segmental Revenue (Rs. crore) 2000 1600 1200 36% 38% 34% 31% 1355 1250 1038 800 633 647 645 613 350 400 0 25% 1638 26% 1199 546
38%
break-up Geographical Break-up (Rs. crore) Segmental Revenue (Rs. crore) 2000 1600 1200 36% 38% 34% 31% 1355 1250 1038 800 633 647 645 613 350 400 0 25% 1638 26% 1199 546 431
34%
k-up Geographical Break-up (Rs. crore) Segmental Revenue (Rs. crore) 2000 1600 1200 36% 38% 34% 31% 1355 1250 1038 800 633 647 645 613 350 400 0 25% 1638 26% 1199 546 431 FY18
Speaking time
Investor Relations Advisors
1
Advertisement
Opening remarks
Investor Relations Advisors
IOL Chemicals & Pharmaceuticals Ltd. Adfactorspr Pvt. Ltd. Mr. Pardeep Kumar Khanna, CFO pardeepkhanna@iolcp.com Snighter Albuquerque snighter.a@adfactorspr.com www.iolcp.com Darshan Mankad darshan.mankad@adfactorspr.com www.adfactorspr.com
Advertisement
← All transcriptsIOLCP stock page →